Introduction {#s1}
============

Completion of the human genome sequence and advances in sequencing are bringing the promises of personalized genetic medicine to fruition. Its applications will not only unravel the mysteries of complex diseases but will also advance the practice of individualized care for disorders whose pathogenic basis is known. It will be important to consider the scenarios in which genetically personalized health care can be applied at costs reflective of society's willingness to pay for health benefits. Currently, there are few rigorous cost-effectiveness analyses of genetic testing policies that lead to changes in the selection of treatments.

Maturity-onset diabetes of the young (MODY) is the most prevalent form of monogenic diabetes, all types of which account for 1--2% of diabetes cases ([@B1]). MODY is classically defined as autosomal dominant, non--insulin dependent diabetes with diagnosis typically before 25 years of age ([@B2]). Additional features of MODY depend upon its molecular genetic basis.

Heterozygous mutations in three genes, *HNF1A*, *HNF4A*, and *GCK,* together account for \>90% of all MODY with a known genetic cause ([@B3]). Diagnosing these subtypes of MODY has important implications for treatment. The first-line therapy for *HNF1A*- and *HNF4A*-MODY is sulfonylurea pills, which result in stable or improved glycemic control and improved quality of life related to diabetes care compared with insulin or metformin therapy ([@B4]--[@B7]). *GCK*-MODY has a unique phenotype of mild, nonprogressive hyperglycemia, with HbA~1c~ typically \<7% (53 mmol/mol). It is not associated with increased risk of microvascular and macrovascular complications seen in other forms of diabetes ([@B8]). Generally, treatment does not change HbA~1c~. Molecular diagnosis of *GCK*-MODY allows pharmacologic therapy to be discontinued and decreases the needed frequency of medical surveillance ([@B9],[@B10]). Genetic diagnosis of MODY additionally allows for identification of at-risk first-degree family members, who have a 50% chance of inheriting a gene mutation.

Screening for MODY is not a routine practice for diabetes classification despite the fact that there is significant clinical overlap between MODY and type 1 and 2 diabetes. Genetic testing is generally pursued only in those with classic features of MODY. However, only ∼50% of subjects with genetically diagnosed MODY meet classic criteria ([@B3]). Apart from clinical features, there are established biomarkers to aid in patient selection for genetic testing, such as high-sensitivity CRP or urinary C-peptide--to--creatinine ratio. However, these tests are not yet in routine clinical practice in the U.S., and not all biomarkers are useful at diabetes onset ([@B11],[@B12]). Irrespective of these clinical considerations, insurance coverage of MODY genetic testing may be denied even in those meeting classic MODY criteria (University of Chicago Monogenic Diabetes Registry, unpublished data,) ([@B13]). Thus, many cases of MODY are being missed. In the case of *GCK*-MODY, *HNF1A*-MODY, and *HNF4A*-MODY, misclassification is likely to lead to overtreatment or unnecessary treatment with increased health care expenditures for individuals ([@B9]). Assessing the economic value of genetic testing for these MODY subtypes in diabetes may clarify practices for selection of patients for testing and inform policy decisions regarding medical insurance coverage for genetic testing costs.

Research Design and Methods {#s2}
===========================

Framework of the Study {#s3}
----------------------

We used a simulation model of diabetes complications to compare a policy of routine genetic testing for *GCK-*, *HNF1A-*, and *HNF4A-*MODY in newly diagnosed patients 25--40 years of age with presumed type 2 diabetes with a policy of no genetic testing. Cost of diabetes care and health outcomes, including rates of diabetes complications, was analyzed for all hypothetical patients. Analysis was conducted from a health care system perspective over the lifetime of the study population. Costs were expressed in 2011 USD. Future costs and quality-adjusted life years (QALYs) were discounted at an annual rate of 3%. The conceptual framework for the cost analysis is depicted in [Fig. 1](#F1){ref-type="fig"}.
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Population Characteristics {#s4}
--------------------------

Our hypothetical cohort consisted of patients between the ages of 25--40 years newly diagnosed with type 2 diabetes. We assumed that the background prevalence of MODY due to mutations in *HNF1A*, *HNF4A*, and *GCK* for this population was 2% and that 98% had true type 2 diabetes ([@B1]). Of those with MODY, we assumed that 65% had *HNF1A*- or *HNF4A*-MODY and 35% had *GCK*-MODY ([@B3]). We used data from the combined National Health and Nutrition Examination Survey (NHANES) 1999--2006 data releases as well as case series of *HNF1A*-, *HNF4A*-, and *GCK*-MODY to assign clinical parameters---including initial HbA~1c~; total cholesterol, HDL, LDL, and triglyceride levels; blood pressure; and BMI---to the cohort ([@B8],[@B14]--[@B16]).

Genetic Testing Impact on Treatment Decisions {#s5}
---------------------------------------------

In our model, hypothetical patients underwent one-time genetic testing for mutations in *GCK*, *HNF1A*, and *HNF4A* within the first year of diabetes diagnosis. We assumed a perfectly sensitive and specific genetic test that would uncover all pathologic mutations. Our model did not allow for more than one type of MODY in a single individual or cooccurrence of MODY and type 2 diabetes in a single patient, though there are rare examples of such in the literature ([@B17],[@B18]).

In both the testing and no testing policies, patients with true type 2 diabetes were treated based on the observed distributions of medications in national studies: 15% no pharmacologic treatment, 57% pills/noninsulin injectables, 14% insulin, and 14% insulin and pills/noninsulin injectables ([@B19],[@B20]). Under the genetic testing policy, those with a diagnosis of MODY were treated according to their genetic subtype: sulfonylureas in the case of *HNF1A*- and *HNF4A*-MODY and no medical treatment in *GCK*-MODY. We assumed that 90% of patients with *HNF1A*- and *HNF4A*-MODY would be successfully treated with sulfonylureas associated with a 1.5% decrease in HbA~1c~ at the time of therapy initiation ([@B4],[@B21]). For those with initial successful sulfonylurea treatment, we modeled increasing rates of sulfonylurea failure with duration of diabetes in hypothetical patients, such that the rate of sulfonylurea failure and insulin initiation was 50% at 20 years postdiagnosis ([@B14]). Hypothetical patients who initially failed sulfonylurea treatment were assigned the same therapy as for those with true type 2 diabetes. For *GCK*-MODY, we assumed that all patients would be able to successfully discontinue therapy without a change in HbA~1c~. We did not account for changes or escalation of therapy over time in the model for those with *GCK*-MODY or true type 2 diabetes. Under the no testing policy, undetected MODY was treated the same as true type 2 diabetes.

Simulation Model for Diabetes Complications {#s6}
-------------------------------------------

To account for future complications and costs of diabetes associated with different policies, we constructed two distinctive diabetes complications models ([Fig. 2](#F2){ref-type="fig"}). For type 2 diabetes and *HNF1A*- and *HNF4A*-MODY, we tracked microvascular-related complications of blindness, renal failure, and amputation and macrovascular complications of angina, myocardial infarction, congestive heart failure, and stroke. Rates of these complications were modeled based upon well-established UK Prospective Diabetes Study (UKPDS) risk equations ([@B22]).

![*A*: Simulation model for complications for type 2 and *HNF1A*- and *HNF4A*-MODY. *B*: Simulation model for complications for *GCK*-MODY.](202fig2){#F2}

For patients with *GCK*-MODY, we only tracked cardiovascular complications because the mild hyperglycemia in *GCK*-MODY is not associated with increased frequency of microvascular complications. In these patients, Framingham cardiovascular risk equations were used to simulate cardiovascular disease and background mortality rates ([@B23]). Hypoglycemia as an adverse reaction to insulin and sulfonylurea therapy was also assessed in all patients ([@B24]).

When we were running the analysis, each hypothetical patient progressed through major categories of complications, as well as a mortality module, over a 1-year cycle. Calculations were done using Excel (Microsoft, Redmond, WA) and \@Risk 5.5 software (Palisades, Newfield, NY). Cycles were repeated over the lifetime of the subject. For each specific scenario, the model was run for 10,000 iterations using Monte Carlo recalculation.

Quality-of-Life Effects {#s7}
-----------------------

To calculate QALYs, we assumed that there were quality-of-life effects of diabetes treatments and complications. Treatment of diabetes with an oral medication was assigned a health utility of 0.77, while treatment with insulin was assigned a utility of 0.64 ([@B25]). Microvascular and macrovascular complications resulted in a decremental change in health state based on published health state utilities ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0410/-/DC1)). If a patient had multiple treatment and complications health states in a given year, we assigned the utility based on the minimum utility method.

Costs {#s8}
-----

The cost of genetic testing was set at 2,580 USD per individual tested, reflecting the cost of simultaneously sequencing *GCK*, *HNF1A*, and *HNF4A* (Commercial Reference Laboratory pricing). Individuals were assigned an annual treatment cost based upon their diabetes treatment group. The annual per-individual treatment cost of insulin-only therapy was 2,641 USD, which includes the cost of insulin, injection supplies, and self--blood glucose monitoring ([@B26]). The annual treatment cost of pills/noninsulin injectables was 767 USD ([@B27]). These costs were combined for those treated with insulin and pills/noninsulin injectables. The annual treatment cost of sulfonylureas in *HNF1A*- and *HNF4A*-MODY was 96 USD ([@B28]). Those on no therapy were assigned a cost of 0 USD. We did not account for self--blood glucose monitoring in non--insulin-treated patients or in patients on no therapy, as the cost-effectiveness and glycemic efficacy of self--blood glucose monitoring has not been established in these populations ([@B29],[@B30]).

Study Outcomes {#s9}
--------------

The main outcome measures were costs and QALYs, based on lifetime risk of complications and treatments, expressed as the incremental cost-effectiveness ratio (ICER) (USD/QALY). Future costs and quality-of-life effects were discounted at an annual rate of 3% with one-way sensitivity analyses performed around the discount rate ([@B31]).

Sensitivity Analysis {#s10}
--------------------

We conducted one-way and two-way sensitivity analyses to evaluate the impact of changes in several key assumptions including MODY prevalence and testing costs on cost utility of a genetic testing policy. We also performed a threshold analysis to understand at which prevalence of MODY a genetic testing policy would become cost saving.

Scenario Analysis {#s11}
-----------------

We also considered that treatment reported in case series of MODY differs from the typical treatment selection reported for type 2 diabetes. MODY case series are likely subject to selection bias; those suspected of having MODY and referred for testing would be more likely to be treated appropriately for their suspected MODY diagnosis than someone misclassified as having type 2 diabetes. Moreover, many case series do not define whether treatment followed MODY diagnosis. Nevertheless, we assessed the impact of modeling treatment of undetected MODY based on data extrapolated from case series as follows: 75% no treatment, 20% pills/noninsulin injectables (modeled to reflect the 2011 annual rates of use of noninsulin antidiabetes treatment), and 5% insulin for *GCK-*MODY and 10% no treatment, 45% pills/noninsulin injectables, and 45% insulin for *HNF1A*- and *HNF4A*-MODY ([@B14],[@B15],[@B32]--[@B34]).

Results {#s12}
=======

Health Effects {#s13}
--------------

In the base case analysis, the genetic testing policy did not significantly change the rate of diabetes complications or overall life expectancy. The genetic testing policy resulted in small quality-of-life benefits of 0.012 QALYs that were due to increased use of pills rather than insulin therapy in the case of *HNF1A*- and *HNF4A*-MODY and a larger percentage of individuals on no therapy in the case of *GCK*-MODY ([Table 1](#T1){ref-type="table"}).
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Cost {#s14}
----

In the base case analysis, the total cost difference between the testing and no testing scenarios was 2,400 USD, accounted for almost entirely by the costs of screening and treatment.

ICER {#s15}
----

Considering the health and cost effects together, the genetic testing policy resulted in an overall ICER of 205,000 USD/QALY for detecting *GCK*-, *HNF1A*-, and *HNF4A-*MODY in incident cases of presumed type 2 diabetes among 25- to 40-year-old patients.

Sensitivity and Scenario Analyses {#s16}
---------------------------------

We performed one- and two-way sensitivity analyses around important parameters varied over plausible ranges to determine how changes would impact the results of the model ([Fig. 3](#F3){ref-type="fig"}). Total costs were most sensitive to the prevalence of MODY and the cost of genetic testing. An increase in MODY prevalence from 2 to 6% resulted in an ICER just over 50,000 USD/QALY, which is often used as a benchmark for assessing cost-effectiveness of a health intervention ([@B35]). Similarly, decreasing the cost of genetic testing from 2,580 to 700 USD led to an ICER of 50,000 USD/QALY.

![Sensitivity analyses for lifetime ICER. SU, sulfonylurea.](202fig3){#F3}

As the pick-up rate of MODY had a large impact on the overall cost-effectiveness of the model, we performed a threshold analysis to determine how prevalent MODY would need to be in the screened population to make a policy of genetic testing cost saving. At an expected pick-up rate of ∼30%, the testing scenario dominated the no testing policy.

Finally, we evaluated the scenario of modeling undetected MODY in the no testing arm with treatment extrapolated from MODY case series. There was no change in QALY, but the ICER increased from 205,000 USD/QALY in the base case to 228,000 USD/QALY. Under this scenario, a MODY prevalence of 8% led to an ICER of ∼50,000 USD/QALY.

Conclusions {#s17}
===========

Currently, there is no uniform policy on insurance coverage decisions for MODY genetic testing. Valuation of MODY genetic testing may help inform and shape coverage policies, and our modeled study is a first step in this process. Conventional benchmarks of cost-effectiveness are typically set at 50,000 USD/QALY ([@B35]), although this threshold has been questioned and benchmarks of 109,000--297,000 USD/QALY may be more reflective of actual U.S. resource-allocation decisions ([@B36]). In our simulation model of type 2 diabetes, screening all hypothetical patients with a clinical diagnosis of type 2 diabetes resulted in an ICER just over 200,000 USD. With a conservative interpretation of cost-effectiveness, small increases in MODY prevalence in our hypothetical cohort to 6% made the genetic screening policy cost-effective with an ICER of ∼50,000 USD. This suggests that testing for subtypes of MODY in an appropriately selected population may be cost-effective. As our conclusions are based on modeled data rather than patient cases, our results may over- or undervalue MODY genetic testing among those with a clinical diagnosis of type 2 diabetes and must be interpreted cautiously. However, they serve as an important indication that MODY genetic testing may improve health outcomes at acceptable societal costs, and thus improved access to testing should be sought.

Our sensitivity analyses showed that the prevalence of MODY in the screened population and the cost of genetic testing had large effects on the cost-effectiveness of a genetic screening policy. An increase in MODY prevalence from 2% in the base case analysis to 6% or a decrease in testing costs to 700 USD resulted in an ICER of ∼50,000 USD/QALY. At a prevalence of just over 30%, a genetic testing policy for MODY was cost saving. Literature has also shown that the prevalence of *HNF1A-*, *HNF4A-*, or *GCK-*MODY in individuals clinically diagnosed with type 2 diabetes but without metabolic features approaches 15% ([@B21]), a prevalence where genetic testing would be predicted to be cost-effective by our model. The likelihood of individuals with classic MODY criteria having a mutation in *HNF1A*, *HNF4A*, or *GCK* is nearly 50% ([@B3]), a prevalence at which genetic testing for MODY would be predicted to be cost saving in our model. Currently available tools, such as a "MODY calculator" could aid in identifying individuals for genetic testing ([@B14],[@B37]). A formal health care policy of routine medical coverage for genetic testing in defined groups of patients for these subtypes of MODY could serve as a model for developing cost-effective health care policies around the application of personalized genetic medicine. Follow-up of the success of such a policy could guide future decisions on expansion of MODY testing coverage as well as form a framework for general decision making in medical insurance coverage policies for genetic testing.

Some important limitations of our model must be considered. The UKPDS outcome model and the natural history of HbA~1c~ are not validated for *HNF1A-* or *HNF4A-*MODY. Thus, our model may have inflated complication rates for *HNF1A-* and *HNF4A-*MODY, accounting for the lack of difference in the testing versus no testing scenarios. These assumptions likely biased against a genetic testing program for MODY.

We modeled *GCK*-MODY without microvascular complications and used data from the Framingham study to model cardiovascular disease. Additionally, we modeled no treatment over the lifetime of hypothetical patients. Many case series support these assumptions. However, Martin et al. ([@B38]) report long-term deterioration in glycemia due to insulin resistance in *GCK*-MODY with 15% of subjects requiring medication at follow-up. This insulin resistance correlated with increases in BMI and age. Insulin resistance is seen under these same circumstances in the nondiabetic population; thus, it is not clear that deterioration in glycemia was a specific feature of *GCK*-MODY.

We extrapolated from the literature to model failure of sulfonylurea therapy over time in those with *HNF1A*- and *HNF4A*-MODY. However, there are little data on the durability of successful use of sulfonylurea therapy in MODY. Studies and case reports have demonstrated deterioration of glycemic control in individuals over time, but there are some reports of successful use of sulfonylurea therapy for decades ([@B6]). Thus, modeled failure rates and therapy changes were based on limited data in our study.

Our model did not account for the effects of identifying family members with MODY, where testing would occur at a substantially lower cost nearly 10-fold less than the cost of propositus testing (Commercial Reference Laboratory pricing). Thus, additional cost savings attributable to this "spillover effect" were not assessed or accounted for, potentially undervaluing the impact of MODY genetic testing.

A final important limitation of our study is the extrapolation of data from MODY case series largely derived from Caucasian European populations for important clinical inputs for the model. As we are interpreting our results in the U.S. context, it is unclear how representative the data are for type 2 diabetes within the U.S. Specifically, the larger non-Caucasian population and higher prevalence of obesity and metabolic syndrome within the U.S. may result in a different background MODY prevalence compared with European countries, and the true U.S. prevalence of MODY is unknown ([@B39]). As practices to identify and genetically diagnose MODY increase in the U.S., we will be able to more accurately assess the incidence and prevalence of MODY and modify health care and economic policy appropriately.

With these limitations taken into account, the results of our simulated model suggest that MODY genetic testing for mutations in *GCK*, *HNF1A*, and *HNF4A* in incident cases of type 2 diabetes is cost-effective if the prevalence of MODY is 6% in the screened cohort. Moreover, as genetic testing costs decrease over time with advancements in sequencing technology, we can expect generalized screening for subtypes of MODY in type 2 diabetes to be a cost-effective application of personalized genetic medicine.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0410/-/DC1>.
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